हिन्दी
English
मराठी
বাংলা
தமிழ்
മലയാളം
ગુજરાતી
తెలుగు
ಕನ್ನಡ
ଓଡ଼ିଶା
Business
Tech
World
Health
NEWS
VIDEOS
PHOTOS
Web Stories
LIVE TV
GO
Latest
India
Ahmedabad
Bengaluru
Chennai
Hyderabad
Kolkata
Mumbai
Pune
Cricket
Success Story
Entertainment
Hollywood
Music
Bollywood
Television
Regional
Movie Review
Lifestyle
Relationship
Travel
Food & Recipes
Fashion
Culture
Spirituality
Business
Economy
Markets
Companies
Real Estate
International Business
Personal Finance
Automobile
Technology
Gadgets
Gaming
Internet & Social Media
Apps
Mobiles
World
Asia
Africa
Americas
Australia-Oceania
Europe
Auto
Mobility
Viral
Diabytes
Fables of Facades
Archived Videos
Newsletter
Fables of Facades
Latest
India
Cricket
Success Story
Entertainment
Lifestyle
Business
World
Auto
Mobility
Viral
Fables of Facades
Archived Videos
Latest
India
Cricket
Success Story
Entertainment
Lifestyle
Business
World
Auto
Mobility
Viral
Fables of Facades
Archived Videos
Advertisement
X
News
AIIMS Director Dr Randeep Guleria
AIIMS Director Dr Randeep Guleria News
COVID-19
14 Aug 2021
COVID-19 third wave depends on people’s behaviour: AIIMS Director Guleria
The AIIMS director believes that the impact of the next wave can be diminished with COVID-appropriate behaviour. "If the third wave comes, then also it will be mild only if people follow COVID-19 appropriate behaviour," said Dr Guleria.
Delta Plus
01 Jul 2021
Not much data to suggest Delta Plus variant more infectious, says AIIMS chief
The Delta Plus variant is a mutated form of the Delta variant of coronavirus, which caused the disastrous second wave in India. "If we follow COVID appropriate behaviour, we'll be safe against any of emerging variants," Guleria assured. Guleria said that more data is required on mixing doses of two different vaccines before it can be recommended.
COVID-19
17 Jun 2021
Delta plus variant may affect efficacy of vaccines to some extent: Guleria
The AIIMS director revealed that the delta plus variant is not yet a concern, adding that “our main aim is to prevent deaths and serious illness". "Currently, the delta plus is a variant of interest. There is not much data to show that this is becoming dominant or this more infectious or causing more mortalities," said AIIMS director.
COVID-19
03 May 2021
Don't get CT-scans if you have mild COVID-19 symptoms, says AIIMS Chief
Dr Randeep Guleria further said that several blood tests for biomarkers are also not needed in mild illness
remdesivir
30 Apr 2021
Remdesivir drug should only be administered in hospital setting: AIIMS chief
The AIIMS chief also explained when a coronavirus infected patient can end home isolation. Guleria remarked that the second wave of COVID-19 has hit tier two and three cities more rapidly. Guleria also underlined against misuse of tocilizumab drug.
Coronavirus
10 Sep 2020
Coronavirus puts strain on mental health: AIIMS Director Randeep Guleria
Guleria said, "Important aspect which has emerged both because of the pandemic, lockdown, and the whole issue of physical distancing and communicating through technology" "The mental health issues have also become something which has affected not only those who have had Covid-19 but even sometimes the normal individuals who are sort of at home" He said that students, old people, have now been confined to a small space and are communicating only through technology rather than physically
AIIMS
11 Aug 2020
Israel shares AI-based technology with AIIMS to help combat COVID-19
The technologies include an AI video-oriented, voice-operated autonomous personal AI assistant robot, an app that can be installed on any mobile phone of the COVID-19 staff Innovative products designed to give clinicians constant contact-free access to patient`s vitals like heart rate and the respiratory rate which improves patient safety It also includes a 12-hour disinfection product called CPD that stays active to protect the surface against new attacks of contamination
Coronavirus
06 Aug 2020
No benefit of plasma therapy in reducing COVID-19 mortality risk: AIIMS
AIIMS Director Dr Randeep Guleria said that no clear mortality benefit of convalescent plasma therapy was seen during a trial conducted among 30 COVID-19 patients This is just an interim analysis and we need to do a more detailed evaluation to see if any sub-group may benefit from plasma therapy, Dr Guleria said He also underlined that plasma has to be tested for its safety and should have sufficient antibody to be useful to COVID-19 patients
Dr Randeep Guleria
06 Apr 2020
Lockdown may continue in India's coronavirus COVID-19 hotspots: AIIMS Director
Dr Guleria said that coronavirus cases have increased in the hotspot and the need of the hour is to confine it to these places only and efforts should be taken contain the deadly virus from growing in other parts of the country.
1110402
1
0
Loading...
Trending news
DNA Video
DNA: Scuffle Over Article 370 in Jammu & Kashmir Assembly: Why Was Abdullah Smiling?
DNA Video
DNA: Secret Strategy Revealed Ahead of Maharashtra Elections?
DNA Video
DNA: What is Bhagwa-e-Hind?
DNA Video
DNA: Trump-Modi Friendship: Pakistan’s Worries Grow
DNA Video
DNA: Trump’s Victory: What Changes Are Coming?
DNA Video
DNA: Yogi’s Bulldozer Politics in Maharashtra
DNA Video
DNA: Article 370 - CM Abdullah’s Gamble Falls Short?
DNA Video
DNA: Supreme Court Upholds Validity of UP Madrasa Act
DNA Video
DNA: US Presidential Elections and its Global Implications
DNA Video
DNA: Yogi Adityanath’s Winning Formula for Upcoming Elections!
Subscribe Now
×
Enroll for our free updates
Please enter full name.
Please enter valid email address.
https://zeenews.india.com/
Subscribe Now
Thank you
×
Cookies Settings
Reject
Accept Cookies
NEWS ON ONE CLICK